PRESS RELEASE

Illumina Announces New TruSeq(TM) SBS Sequencing Kit for the Genome Analyzer

New Kit Helps Paint Truest Picture of Genome With Longer Reads and Enhanced Data Quality

SAN DIEGO, Jul 26, 2010 (BUSINESS WIRE) --

Illumina, Inc. (NASDAQ:ILMN) today announced the launch of its TruSeq SBS Sequencing kit that will enable high-quality paired end reads of 150 base pairs (bp), increase the output of high-quality base calls, and enhance throughput to greater than 95 Gigabases (Gb) of high-quality base pairs per run on Illumina's Genome Analyzer (GA) sequencing system. The kit, which the company has commenced shipping broadly, is the first in a series of new kits that will further advance data quality, ease of use and economical sequencing on the company's sequencing platforms. Individual products within the family of TruSeq reagents will be specifically formulated for each Illumina sequencing platform to best leverage the features of that system to provide the highest yield and quality of data.

"At NCGR, we're using TruSeq SBS chemistry to routinely generate over 85% Q30 data for our 100 bp runs, which is a dramatic improvement in both accuracy and output," said Gregory May, President and Chief Operating Officer at the National Center for Genome Resources. "In addition, we're now able to perform paired end reads up to 150 bp on the Genome Analyzer, which will help us greatly in both our *de novo* sequencing studies as well as our ongoing agriculture sequencing projects."

Coupled with advances in algorithms, the TruSeq SBS Sequencing kit will enable researchers to increase the yield of Q30 base calls and generate approximately 500 million perfect reads per 2x100 bp run, setting a new standard for output of high-quality data from the GA. The yield of perfect reads is an important indicator of a system's overall quality and helps greatly in mapping accuracy, yield and overall coverage of a genome.

"The TruSeq family of reagents is the newest in a long line of sample preparation and chemistry advancements focused on enhancing ease of use, data quality and economical sequencing," said Christian Henry, Senior Vice President and General Manager of Life Sciences at Illumina. "The TruSeq SBS Sequencing kit will provide researchers with even greater accuracy on the Genome Analyzer to generate data with higher mapping rates as well as lower false positive and negative rates. These improvements will materially enhance researchers' ability to paint the truest picture of the genome."

Illumina anticipates following up the release of the TruSeq SBS Sequencing kit with TruSeq Cluster Generation kits and TruSeq Sample Preparation kits for both DNA and RNA applications on the GA later this year. The family of TruSeq reagents will provide Illumina sequencing users with the most optimal workflow and highest quality data possible on the company's platforms.

For more information about Illumina's next-generation sequencing tools, please visit: http://www.illumina.com/?utm_source=various&utm_medium=press_release_07262010&utm_campaign=truseq.

About Illumina

Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the

RECENT ARTICLES

Select an area of interest


Missed opportunities for cancer patients


In Brazil, building genomic evidence for a better tomorrow


A new push to remove barriers to genome sequencing

date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

SOURCE: Illumina, Inc.

Illumina, Inc.
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
858-202-4507
pfromen@illumina.com
or
Media:
Wilson Grabill
Sr. Manager, Public Relations
858-882-6822
wgrabill@illumina.com

Previous Article
Illumina Reports Financial Results for Second Quarter 2010

Next Article
Illumina Announces Appointment of Melina Cimler as Vice President, Quality and Regulatory Affairs

illumina

INNOVATIVE TECHNOLOGIES

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

Cookies Settings Update Subscription preferences Privacy Policy

© 2024 Illumina, Inc. All rights reserved.

For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Careers
Contact Us